Status:
COMPLETED
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
Lead Sponsor:
Virginia Commonwealth University
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Hepatitis C
Cirrhosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibr...
Detailed Description
Portal hypertension develops in patients with advanced fibrosis and cirrhosis and is the primary driving force leading to complications of cirrhosis, hepatic decompensation and mortality in patients w...
Eligibility Criteria
Inclusion
- Completion of HALT-C Trial, in either treatment or non-treatment arm
Exclusion
- Non-completion of HALT-C Trial
- Patients who do not wish to be treated with peginterferon after the first portal pressure measurement
- Hepatocellular Carcinoma
- Underlying autoimmune disorder
- Currently being treated with immune suppressive agent
- Illicit drug use
- Alcohol use of more than 6 grams per day
- Advanced cardiopulmonary disease
- Uncontrolled diabetes mellitus
- Patients who, in the opinion of the investigator, should not participate in this trial
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00252642
Start Date
November 1 2005
End Date
September 1 2007
Last Update
March 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298